Importance of Multi-lineage Hematologic Involvement and Hypoalbuminemia at Diagnosis in Patients With "Risk-organ" Multi-system Langerhans Cell Histiocytosis

被引:13
|
作者
Luis Braier, Jorge [1 ]
Rosso, Diego [1 ]
Latella, Antonio [2 ]
Chantada, Guillermo [1 ]
Ozuna, Blanca [3 ]
Ripoli, Mario [4 ]
Scopinaro, Marcelo [1 ]
机构
[1] Hosp Nacl Pediat Juan P Garrahan, Dept Hematol Oncol, RA-1245 Buenos Aires, DF, Argentina
[2] Hosp Nacl Pediat Juan P Garrahan, Dept Pediat, RA-1245 Buenos Aires, DF, Argentina
[3] Hosp Nacl Pediat Juan P Garrahan, Dept Nutr, RA-1245 Buenos Aires, DF, Argentina
[4] Univ Buenos Aires, Dept Pediat, Buenos Aires, DF, Argentina
关键词
anemia; thrombocytopenia with or without leukopenia; hypoalbuminemia; prognosis; Langerhans cell histiocytosis; RANDOMIZED TRIAL; CHILDREN; DISEASE; ALPHA;
D O I
10.1097/MPH.0b013e3181d7acc5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim: To perform a risk factor analysis in patients with "risk organ" multi-system Langerhans cell histiocytosis at diagnosis. Methods: From 1987 to 2007, 77 patients were analyzed. A univariate analysis of the variables, age <2 years, lungs, spleen and hepatic involvement, presence of >2 risk involved organs, hypoalbuminemia and the presence of isolated anemia, anemia with thrombocytopenia with or without leukopenia at diagnosis was performed. Statistically significant variables were combined and entered into a multivariate analysis. Results: Fifty-six and 66 evaluable patients had hematologic and hepatic involvement at diagnosis, respectively. Among the hematologic patients, the subgroup of anemia with thrombocytopenia with or without leukopenia showed a significantly lower 5-year survival than the subgroup of isolated anemia (0.19 vs. 0.87, respectively; P = 0.0001). Of all the patients, those with hypoalbuminemia had a 5-year survival of 0.16 compared with those with normal albumin levels, who had a 5-year survival of 0.65 (P < 0.0001). In multivariate analysis, only anemia with thrombocytopenia with or without leukopenia and hypoalbuminemia were the independent risk factors (relative risk 3.77; confidence interval, 1.7-8.4; P < 0.0011 and relative risk 2.59; confidence interval, 1.24-5.4; P < 0.0112). Conclusions: Anemia with thrombocytopenia with or without leukopenia and hypoalbuminemia, were associated with worse prognosis in multi-system Langerhans cell histiocytosis. Other therapeutic strategies should be considered at diagnosis or early during the initial treatment for this high risk subgroup of patients.
引用
收藏
页码:E122 / E125
页数:4
相关论文
共 47 条
  • [1] Langerhans Cell Histiocytosis in adults with Multi-system Involvement
    Mikhaimer, Nadia C.
    Egberts, Friederike
    Hauschild, Axel
    Schwarz, Thomas
    Kaehler, Katharina C.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2012, 10 (09): : 679 - 679
  • [2] Impact of reactivation on the sequelae of multi-system Langerhans cell histiocytosis patients
    Morimoto, Akira
    Kobayashi, Ryoji
    Maeda, Miho
    Asami, Keiko
    Bessho, Fumio
    Imashuku, Shinsaku
    PEDIATRIC BLOOD & CANCER, 2008, 50 (04) : 931 - 932
  • [3] Langerhans cell histiocytosis presenting as a multi-system disorder in an infant
    Hu, Sheng
    Wang, Wenging
    Wang, Chen
    Ma, Rui
    Xiao, Zhaoyang
    Dong, Hailong
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2012, 51 (06) : 709 - 712
  • [4] Impact of reactivation on the sequelae of multi-system Langerhans cell histiocytosis patients - Response
    Pollono, Daniel
    Rey, Guadalupe
    Latella, Antonio
    Rosso, Diego
    Chantada, Guillermo
    Braier, Jorge
    PEDIATRIC BLOOD & CANCER, 2008, 50 (04) : 932 - 932
  • [5] Cutaneous manifestation in multi-system Langerhans cell histiocytosis (LCH): a clue for early diagnosis
    Jahnke, I.
    Stieler, K. M.
    Bartels, N. Garcia
    Hundsdoerfer, P.
    Roewert-Huber, H. -J.
    Blume-Peytavi, U.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2014, 12 : 39 - 40
  • [6] MULTISYSTEM LANGERHANS CELL HISTIOCYTOSIS (MS-LCH): PREDICTIVE VALUE OF SCORING SYSTEM BASED ON RISK-ORGAN INVOLVEMENT (RO) AT DIAGNOSIS
    Poetschger, Ulrike
    Arico, Maurizio
    Astigarraga, Itziar
    Braier, Jorge
    Donadieu, Jean
    Gadner, Helmut
    Grois, Nicole
    Henter, Jan-Inge
    Janka-Schaub, Gritta
    McClain, Kenneth
    Thiem, Elfriede
    Weitzman, Sheila
    Windebank, Kevin
    Ladisch, Stephan
    Minkov, Milen
    PEDIATRIC BLOOD & CANCER, 2015, 62 : S136 - S136
  • [7] REACTIVATION AND SEQUELAE IN MULTI-SYSTEM LANGERHANS CELL HISTIOCYTOSIS AT A SINGLE INSTITUTION
    Braier, Jorge
    Rosso, Diego
    Chantada, Guillermo
    Latella, Antonio
    Balancini, Blanca
    Bernaldez, Patricia
    Vaiani, Elisa
    Goldberg, Julio
    PEDIATRIC BLOOD & CANCER, 2011, 56 (04) : 691 - 691
  • [8] Remission of Congenital Multi-system Type Langerhans Cell Histiocytosis with Chemotherapy
    Tamefusa, Kosuke
    Ishida, Hisashi
    Washio, Kana
    Ishida, Toshiaki
    Morita, Hirosuke
    Shimada, Akira
    ACTA MEDICA OKAYAMA, 2019, 73 (01) : 61 - 65
  • [9] MULTI-SYSTEM LANGERHANS CELL HISTIOCYTOSIS PRESENTS AS BLUEBERRY MUFFIN RASH
    Fabrizio, V.
    Menghani, H.
    Velez, M.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2016, 64 (02) : 550 - 550
  • [10] DABRAFENIB FOR RESISTANT BRAF MUTATED MULTI-SYSTEM LANGERHANS CELL HISTIOCYTOSIS
    Hays, Julia Allyson
    PEDIATRIC BLOOD & CANCER, 2023, 70 : S19 - S20